Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the hepatitis competence net project;Entwicklung von sozioökonomischen charakteristika, lebensqualität und wissensstand bei patienten mit hepatitis C während des projektes kompetenznetz hepatitis

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 1, 2008, Pages 22-33

  Niederau, Claus ^a   Bemba, C ^b   Kautz, A ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Deutsche Leberhilfe eV   (Germany)

Author keywords

Hepatitis C virus; Interferon; Liver biopsy; Liver cirrhosis; Quality of life; Ribavirin

Indexed keywords

ARTICLE; EMPLOYMENT; HEALTH INSURANCE; HEPATITIS C; HUMAN; MENTAL PERFORMANCE; OCCUPATIONAL DISEASE; PHYSIOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIOECONOMICS;

ANTIVIRAL AGENTS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH; INTERFERONS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; SELF-HELP GROUPS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 39349096673     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963534     Document Type: Article

References (46)

1. Davis GL, Balart LA, Schiff ER et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334-343
2. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV: Results of HQL. Dig Dis Sci 1996; 41: 75-80
3. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C infection causes a significant reduction in HRQOL in the absence of cirrhosis. Hepatology 1998; 27: 209-212
4. Sladden TJ, Hickey AR, Dunn TM et al. Hepatitis C virus infection: impacts on behaviour and lifestyle. Aust N Z J Public Health 1998; 22: 509-511
5. Neary MP, Cort S, Bayliss MS et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19: 77-85
6. Ware JE, Bayliss MS, Mannocchia. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999; 30: 550-555
7. Bonkovsky HL, Woolley JM, The Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-270
8. Rodger AL, Jolley D, Thompson SC et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-1301
9. McHutchison JG, Ware JE Jr, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Hepatology 2001; 34: 140-147
10. Bernstein D, Kleinman L, Barker CM et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-708
11. Fontana RJ, Hussain KB, Schwartz SM et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Hepatology 2002; 36: 401-407
12. Gallegos-Orozco JF, Fuentes AP, Argueta JG et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003; 34: 124-129
13. Wright M, Forton D, Main J et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005; 12: 58-66
14. Niederau C, Bemba G, Kautz A. Sozio-ökonomische Charakteristika, Lebensqualität und Wissensstand bei Patienten mit Hepatitis C-Virusinfektion in Deutschland. Z Gastroenterol 2006; 44: 305-317
15. Fontana RJ, Hussain KB, Schwartz SM et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Hepatology 2002; 36: 401-407
16. Häuser W, Zimmer C, Schiedermaier P et al. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004; 66: 954-958
17. Goh J, Coughlan B, Quinn J et al. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833-838
18. Dwight MM, Kowdley KV, Russo JE et al. Depression, fatigue and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311-317
19. Hussain KB, Fontana RJ, Moyer CA et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2734-2744
20. Zickmund S, Ho EY, Masuda M et al. "They treated me like a leper". Stigmatization and the quality of life of patients with chronic hepatitis C. J Gen Intern Med 2003; 18: 835-844
21. Sherman KE, Sherman SN, Chenier T et al. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164: 2377-2382
22. Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001; 25: 355-361
23. Hassoun Z, Willems B, Deslauriers J et al. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002; 47: 2674-2681
24. Glacken M, Coates V, Kernohan G et al. The experience of fatigue for people living with hepatitis C. J Clin Nurs 2003; 12: 244-252
25. Filippini D, Colombo F, Jann S et al. Central nervous system involvement in patients with HCV-related cryoglobulinemia: literature review and a case report. Reumatismo 2002; 54: 150-155
26. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440-446
27. Kramer L, Bauer E, Funk G et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 3: 349-354
28. Morsica G, Bernardi MT, Novati R et al. Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 1997; 5: 252-254
29. Forton DM, Thomas HC, Murphy CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439
30. Hilsabeck RC, Hassanein TI, Carlson MD et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847-854
31. Weissenborn K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851
32. Kraus MR, Schäfer A, Csef H et al. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 377-384
33. Bullinger M, Kirchberger I. SF36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe Verlag, 1998
34. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62-65
35. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52
36. Kraus MR, Schäfer A, Faller H et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 6: 708-714
37. Horiwaka N, Yamazaki T, Izumi N et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiaty 2003; 25: 34-38
38. Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681
39. Kraus MR, Schäfer A, Wißmann S et al. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005; 77: 90-100
40. Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432
41. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
42. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
43. Hadziyannis SJ, Sette HJr, Morgan TR et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
44. Schäfer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-451
45. Marcellin P, Lau GK, Bonino F et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
46. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19: 67-75